The role of solution heat treatment on corrosion and mechanical behaviour of Mg-Zn biodegradable alloys

The mechanical properties and bio-corrosion behaviours of T4 solid solution heat-treated Mg–1.5Zn and Mg–9Zn alloys at 340°C under different heat treatment durations were investigated. In vitro corrosion behaviour of the heat-treated alloys immersed in simulated body fluid (SBF) were measured by electrochemical, hydrogen evolution and mass loss tests. Surface examination and analytical studies were carried out using optical and scanning electron microscopy, EDX, and X-ray diffractometry. The results show that the grains size of both the alloys apparently remained unchanged after T4 treatment. T4 treatment at 340°C for 6?h slightly increased the strength and elongation of Mg–1.5Zn alloy while it significantly improved the strength and elongation of the Mg–9Zn alloy because of the presence of residual Mg51Zn20 and Mg12Zn13 secondary phase at the grain boundary. The results of electrochemical tests show that the corrosion rate of both the alloys decrease with increasing treatment temperature. The result also shows corrosion resistance of both the T4 tread alloys much better than that of as-cast samples. The corrosion mechanism exhibited that the occurrence of galvanic and pitting corrosion, which varied with the alloy composition and treatment time

Biomolecular Corona Dictates Aβ Fibrillation Process

Amyloid beta (Aβ), which forms toxic oligomers and fibrils in brain tissues of patients with Alzheimer's disease, is broadly used as a model protein to probe the effect of nanoparticles (NPs) on oligomerization and fibrillation process. However, majority of the reports in the field, ignored the effect of biomolecular corona on the fibrillogenesis of the Aβ proteins. Biomolecular corona, which is a layer composed of various types of biomolecules that covers surface of NPs upon their interaction with biological fluids, determines the biological fates of NPs. Therefore, during in vivo interaction of NPs with Aβ protein, what the Aβ actually "sees" is the human plasma- and/or cerebrospinal fluid (CSF)-biomolecular coated NPs rather than the pristine surface of NPs. Here, to mimic the in vivo effects of therapeutic NPs as anti-fibrillation agents, we probed the effects of biomolecular corona derived from human CSF and/or plasma on Aβ fibrillation. The results demonstrated that the type of biomolecular corona can dictate the inhibitory or acceleratory effect of NPs on Aβ1-42 and Aβ25-35 fibrillation processes. More specifically, we found that the plasma biomolecular corona coated gold NPs, with sphere and rod shapes, has less inhibitory effects on Aβ1-42 fibrillation kinetics compared to CSF biomolecular corona coated- and pristine- NPs. Opposite results obtained for Aβ25-35 peptide, where the pristine NPs accelerated the Aβ25-35 fibrillation process while corona-coated ones demonstrated an inhibitory effect. In addition, the CSF biomolecular corona had less inhibitory effects than those obtained from plasma. © 2018 American Chemical Society

Magnetic bio-metal–organic framework nanocomposites decorated with folic acid conjugated chitosan as a promising biocompatible targeted theranostic system for cancer treatment

© 2019 Elsevier B.V. In this work, a multifunctional magnetic Bio-Metal-Organic Framework (Fe 3 O 4 @Bio-MOF) coated with folic acid-chitosan conjugate (FC) was successfully prepared for tumor-targeted delivery of curcumin (CUR) and 5-fluorouracil (5-FU) simultaneously. Bio-MOF nanocomposite based on CUR as organic linker and zinc as metal ion was prepared by hydrothermal method in the presence of amine-functionalized Fe 3 O 4 magnetic nanoparticles (Fe 3 O 4 @NH 2 MNPs). 5-FU was loaded in the magnetic Bio-MOF and the obtained nanocarrier was then coated with FC network. The prepared nanocomposite (NC) was fully characterized by high resolution-transmission electron microscope (HR-TEM), field emission scanning electron microscopy (FE-SEM), Dynamic light scattering (DLS), X-ray diffraction analysis (XRD), thermogravimetric analysis (TGA), vibrating sample magnetometry (VSM), nuclear magnetic resonance (NMR), and UV–vis analyses. In vitro release study showed controlled release of CUR and 5-FU in acidic pH confirming high selectivity and performance of the carrier in cancerous microenvironments. The selective uptake of 5-FU-loaded Fe 3 O 4 @Bio-MOF-FC by folate receptor-positive MDA-MB-231 cells was investigated and verified. The ultimate nanocarrier exhibited no significant toxicity, while drug loaded nanocarrier showed selective and higher toxicity against the cancerous cells than normal cells. SDS PAGE was also utilized to determine the protein pattern attached on the surface of the nanocarriers. In vitro and in vivo MRI studies showed negative signal enhancement in tumor confirming the ability of the nanocarrier to be applied as diagnostic agent. Owing to the selective anticancer release and cellular uptake, acceptable blood compatibility as well as suitable T 2 MRI contrast performance, the target nanocarrier could be considered as favorable theranostic in breast cancer

Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of gold‑iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics

© 2017 Elsevier B.V. Brain tumor is a lethal, fast growing cancer and a difficult case for treatment. Receptor-mediated endocytosis has been recognized as one of the most effective methods for drug delivery to brain tissue by overcoming obstacles associated with conventional therapeutics. In this work, a targeted theranostic drug delivery system (DDS) was prepared based on gold‑iron oxide nanocomposites (Fe3O4@Au NCs). Lipoic acid-curcumin (LA-CUR) was synthesized and introduced as a novel anticancer drug, and glutathione (GSH) was exploited as the targeting ligand. Both LA-CUR and GSH were easily attached to Fe3O4@Au NCs via Au-S interaction. As a negatively charged nanocarrier, the prepared DDS showed relatively less protein adsorption. Accordingly, hemocompatibility assays (complement, platelet, and leucocyte activation) revealed its hemocompatible virtue, especially in respect of free LA-CUR. GSH functionalization led to 2-fold increase of cellular uptake in GSH receptor-positive astrocyte cells which could primarily indicate the probable ability of the DDS to bypass BBB. Cytotoxicity and apoptosis assays together showed the noticeably enhanced cytotoxicity of LA-CUR against cancerous U87MG cells (IC50 = 2.69 μg/ml) in comparison with curcumin (IC50 = 21.31 μg/ml); moreover, the DDS demonstrated relatively higher cytotoxicity against cancerous U87MG cells than normal astrocyte cells which was in accordance with pH sensitive mechanism of LA-CUR release. Besides, the results of in vitro magnetic resonance imaging (MRI) (relaxation rate (r2) = 80.73 (s− 1·mM− 1)) primarily revealed that the DDS can be applied as a negative MRI contrast agent. In sum, the prepared DDS appeared to be a promising candidate for brain cancer treatment and a favorable MRI contrast agent

2019 IUSTI‐Europe guideline for the management of anogenital warts

This guideline is an update of the 2011 European Guideline for the Management of Anogenital Warts. It is intended to support best practice in the care of patients with anogenital warts by including evidence-based recommendations on diagnosis, treatment, follow-up and advice to patients. It is intended for use by healthcare professionals in sexual healthcare or dermato-venereology clinics in Europe but may be adapted for use in other settings where the management of anogenital warts is undertaken. As a European guideline, recommendations should be adapted according to national circumstances and healthcare systems. Despite the availability of vaccine to prevent HPV types 6 and 11, the cause of >95% anogenital warts, they remain an important and frequent health problem. The previous systematic review of randomized controlled trials for anogenital warts was updated. The changes in the present guideline include the following: Updated background information on the prevalence, natural history and transmission of human papillomavirus (HPV) infection and anogenital warts. Key recommendations for diagnosis and treatment have been graded according to the strength of the recommendation and the quality of supporting evidence. 5-fluorouracil, local interferon and photodynamic therapy have been evaluated and included as potential second-line treatment options. Evidence of the impact of HPV vaccination on the incidence of anogenital warts has been updated